ACTonDiabetes-Aftercare. A pragmatic randomised-controlled trial for the evaluation of an acceptance and commitment-based internet intervention for people living with diabetes type 1 or type 2.

ACTonDiabetes-Aftercare. A pragmatic randomised-controlled trial for the evaluation of an acceptance and commitment-based internet intervention for people living with diabetes type 1 or type 2. - ACTonDiabetes-Aftercare

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00016738

Enrollment

210

Registered

2019-06-24

Start date

2019-06-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E10 E11

Interventions

Group 1: intervention group: access to ACTonDiabetes-Aftercare following in-patient stay Group 2: control group: enhanced treatment as-usual (TAU+)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of diabetes mellitus type 1 or type 2, elevated level of diabetes-related distress: cut-off PAID =32 (untransformed raw value, this equals the transformed scale value of PAID=40, after multiplying the raw value by 1.25), sufficient knowledge of German language, Internet access, valid e-mail-address, recently treated as an inpatient at the diabetes centre (< 4 weeks), written informed consent

Exclusion criteria

Exclusion criteria: other specific types of diabetes, cognitive impairment

Design outcomes

Primary

Measure	Time frame
diabetes-related distress (PAID) at post-treatment (T2)	—

Secondary

Measure	Time frame
Depression (PHQ-8), Psychological well-being (WHO-5), Psychological Flexibility (FAH-II), Quality of Life (AQoL-8D), diabetes-related self-management (DSMQ), Fear of Progression (FoP-Q-SF), Side-Effects (INEP), Healthcare utilisation (TiC-P), Emotion Regulation (ERQ), Centrality of Life Events (CES), Gratitude (GQ-6), Therapeutical alliance (WAI), Satisfaction with the intervention (ZUF-8), Diabetes Acceptance (AADQ), Metacognition (MaSCS). Measuring points: Screening, T0=Baseline, T1=5 weeks post-randomisation, T2=10 weeks post-randomisation (=post-measurement), T3=6 months post-randomisation, T4=12 months post-randomisation	—

Measure

Time frame

Depression (PHQ-8), Psychological well-being (WHO-5), Psychological Flexibility (FAH-II), Quality of Life (AQoL-8D), diabetes-related self-management (DSMQ), Fear of Progression (FoP-Q-SF), Side-Effects (INEP), Healthcare utilisation (TiC-P), Emotion Regulation (ERQ), Centrality of Life Events (CES), Gratitude (GQ-6), Therapeutical alliance (WAI), Satisfaction with the intervention (ZUF-8), Diabetes Acceptance (AADQ), Metacognition (MaSCS). Measuring points: Screening, T0=Baseline, T1=5 weeks post-randomisation, T2=10 weeks post-randomisation (=post-measurement), T3=6 months post-randomisation, T4=12 months post-randomisation

—

Countries

Germany

Contacts

Public ContactEileen Bendig

Universität UlmInstitut für Psychologie und PädagogikAbteilung für Klinische Psychologie und Psychotherapie

eileen.bendig@uni-ulm.de073105032807

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 22, 2026